Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BILR 355 BS /1B, current low dose formulation
Drug: BILR 355 BS /1B, current high dose formulation
Drug: BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulation
Drug: BILR 355 BS - Suspension low dose
Drug: Ritonavir
Drug: BILR 355 BS - Hammer Milled (HM) + Sodium Dodecyl Sulfate (SDS) formulation
Drug: BILR 355 BS - Suspension high dose

First Posted Date: 2014-10-09

Last Posted Date: 2018-08-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 88

Registration Number: NCT02259868

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of KUC 7483 CL Tablets in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: KUC 7483 CL - single rising dose
Drug: Placebo
Other: standardized high fat meal

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02259764

Dose Tolerance Study in Healthy Male Volunteers After Intranasal Application of Epinastine Nasal

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Epinastine nasal
Drug: Placebo

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 39

Registration Number: NCT02260037

Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan/Amlodipine
Other: high fat, high caloric meal

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT02259777

In Vitro/in Vivo Correlation (IVIVC) for Oral Slow Release (SR) Tablets Pramipexole in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Other: High fat, high caloric meal
Drug: Pramipexole SR C2B
Drug: Pramipexole IR tablets
Drug: Pramipexole SR C2A
Drug: Pramipexole SR C
Drug: Pramipexole SR C2

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT02260024

Pharmacokinetics of Telmisartan Alone and in Combination With Amlodipine in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan
Drug: Amlodipine

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 38

Registration Number: NCT02259816

Effects of Food on the Bioavailability and Pharmacokinetic Profile of Itasetron After a Single Oral Dose in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Itasetron tablet
Drug: Itasetron infusion
Other: high fat breakfast

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT02259985

Study to Investigate Safety and Tolerability of BI 1744 CL in Free Dose Combination With Tiotropium Bromide Both Administered by Respimat® in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 1744 CL
Drug: Tiotropium bromide

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT02259946

Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Atrovent® CFC inhalation aerosol
Drug: Ipratropium bromide HFA-134a inhalation aerosol
Drug: Placebo

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 41

Registration Number: NCT02260011

Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: Tipranavir
Drug: Ritonavir
Drug: Pegylated interferon
Drug: Ribavirin

First Posted Date: 2014-10-09

Last Posted Date: 2025-01-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02259855

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy